LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for Statins
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia
Trial Timeline
Apr 1, 2010 → Jun 1, 2011
NCT ID
NCT01105975About LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for Statins
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for Statins is a phase 2 stage product being developed by Eli Lilly for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01105975. Target conditions include Dyslipidemia.
What happened to similar drugs?
15 of 20 similar drugs in Dyslipidemia were approved
Approved (15) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01105975 | Phase 2 | Completed |
Competing Products
20 competing products in Dyslipidemia